

Oncology Today with Dr Neil Love: Recently Approved Agents in Multiple Myeloma (Faculty Presentation)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following drug types best describes the mechanism of action of selinexor, which was recently approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM)?**
 - a. Antibody-drug conjugate
 - b. Inhibitor of the nuclear export protein XPO1**
 - c. Anti-CD38 antibody
- 2. Which of the following proteins is the target on the surface of MM cells at which the antibody-drug conjugate belantamab mafodotin is directed?**
 - a. CD38
 - b. PD-L1
 - c. BCMA**
- 3. Which of the following strategies has been recommended as being effective in managing the nausea associated with selinexor/dexamethasone for patients with R/R MM?**
 - a. Dose reduction only
 - b. Antiemetic medication only
 - c. Both dose reduction and antiemetic medication**
- 4. The Phase III ICARIA-MM study investigating isatuximab with pomalidomide/dexamethasone for patients with R/R MM demonstrated which of the following results on the isatuximab arm?**
 - a. A significant improvement in progression-free survival**
 - b. No significant improvement in progression-free survival